Aarhus University-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2023

  1. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

    OncoImmunology, Vol. 12, Núm. 1

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177